Sutimlimab

Classical Complement Pathway Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Sutimlimab is a drug in the Classical Complement Pathway Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2022. Its mechanism of action is classified as Classical Complement Pathway Inhibitors. DrugCentral lists 1 molecular target, including C1S. Recorded indications include Cold autoimmune hemolytic anemia.

• Drug class: Classical Complement Pathway Inhibitor.
• Mechanism of action: Classical Complement Pathway Inhibitors.
• Molecular targets: C1S (1 listed in DrugCentral).
• Indications: Cold autoimmune hemolytic anemia.
• ATC code: L04AJ04 (Complement inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Cold autoimmune hemolytic anemia

Mechanism & targets

• Mechanism of action (MoA): Classical Complement Pathway Inhibitors
• Established pharmacologic class: Classical Complement Pathway Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Complement C1s subcomponent	C1S	inhibitor	Kd 9.59

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2022-11-15	EMA	—	GENZYME EUROPE BV	Yes
2022-06-20	PMDA	—	SANOFI K.K	Yes
2022-02-04	FDA	—	BIOVERATIV THERAPEUTICS INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
L04AJ04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Complement inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Haemolysis	89.1
Disseminated varicella zoster virus infection	54.6
Hepatitis viral	51.8

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 2049079-64-1
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sutimlimab used for?

DrugCentral lists the following indications for Sutimlimab: Cold autoimmune hemolytic anemia.

How does Sutimlimab work?

Sutimlimab is classified as Classical Complement Pathway Inhibitors; its molecular targets in DrugCentral include C1S (inhibitor).

When was Sutimlimab first approved?

Sutimlimab was first approved by the FDA in 2022.

What drug class does Sutimlimab belong to?

Sutimlimab is in the Classical Complement Pathway Inhibitor class.

Sources

• DrugCentral drug card 5512 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297832 — compound record and bioactivity
• DrugBank DB14996 — drug record
• FDA UNII GNWE7KJ995 — substance identity
• DailyMed: FDA labels for Sutimlimab — current prescribing information (label search)
• UniProt P09871 (C1S) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.